Blood-based protein biomarkers for diagnosis of Alzheimer disease.
Blood-based protein biomarkers for diagnosis of Alzheimer disease.
复制标题
DOI：
10.1001/archneurol.2012.1282
复制
发表时间：
2012-10
影响因子：
--
通讯作者：
Australian Imaging Biomarker and Lifestyle Research Group
中科院分区：
文献类型：
--
作者：
Doecke JD;Laws SM;Faux NG;Wilson W;Burnham SC;Lam CP;Mondal A;Bedo J;Bush AI;Brown B;De Ruyck K;Ellis KA;Fowler C;Gupta VB;Head R;Macaulay SL;Pertile K;Rowe CC;Rembach A;Rodrigues M;Rumble R;Szoeke C;Taddei K;Taddei T;Trounson B;Ames D;Masters CL;Martins RN;Alzheimer's Disease Neuroimaging Initiative;Australian Imaging Biomarker and Lifestyle Research Group
目的：确定诊断阿尔茨海默病（AD）的血浆生物标志物。结合靶向生物标志物和临床病理数据，对151种多重分析物进行基线血浆筛查。一般基于社区的、前瞻性的、纵向的老龄化研究。共有754名健康个体作为对照，207名AD患者来自澳大利亚成像生物标志物和生活方式研究（AIBL）队列，这些生物标志物在58名健康对照和112名阿尔茨海默病神经成像倡议（ADNI）队列中得到验证。我们确定了一个生物标志物面板，包括AD患者的标志物显著升高（皮质醇、胰腺多肽、胰岛素样生长因子结合蛋白2、β2微球蛋白、血管细胞粘附分子1、癌胚抗原、基质金属蛋白2、CD40、巨噬细胞炎症蛋白1α、超氧化物歧化酶和同型半胱氨酸）和降低（载脂蛋白E、表皮生长因子受体、血红蛋白、钙、锌、白细胞介素17和白蛋白）。来自AIBL队列的交叉验证准确性测量在敏感性和特异性方面达到85%(3.0%)，在受试者工作特征曲线下面积方面达到93%（3.0）。使用ADNI队列的第二次验证获得了80%（3.0%）的敏感性和特异性和85%（3.0）的接受者工作特征曲线下面积的准确性。本研究确定了一组血浆生物标志物，以高灵敏度和特异性将AD患者与认知健康对照者区分开来。AIBL队列的交叉验证和ADNI队列的进一步验证提供了强有力的证据，表明所鉴定的生物标志物对AD诊断很重要。
To identify plasma biomarkers for the diagnosis of Alzheimer disease (AD). Baseline plasma screening of 151 multiplexed analytes combined with targeted biomarker and clinical pathology data. General community-based, prospective, longitudinal study of aging. A total of 754 healthy individuals serving as controls and 207 participants with AD from the Australian Imaging Biomarker and Lifestyle study (AIBL) cohort with identified biomarkers that were validated in 58 healthy controls and 112 individuals with AD from the Alzheimer Disease Neuroimaging Initiative (ADNI) cohort. A biomarker panel was identified that included markers significantly increased (cortisol, pancreatic polypeptide, insulinlike growth factor binding protein 2, β2 microglobulin, vascular cell adhesion molecule 1, carcinoembryonic antigen, matrix metalloprotein 2, CD40, macrophage inflammatory protein 1α, superoxide dismutase, and homocysteine) and decreased (apolipoprotein E, epidermal growth factor receptor, hemoglobin, calcium, zinc, interleukin 17, and albumin) in AD. Cross-validated accuracy measures from the AIBL cohort reached a mean (SD) of 85% (3.0%) for sensitivity and specificity and 93% (3.0) for the area under the receiver operating characteristic curve. A second validation using the ADNI cohort attained accuracy measures of 80% (3.0%) for sensitivity and specificity and 85% (3.0) for area under the receiver operating characteristic curve. This study identified a panel of plasma bio-markers that distinguish individuals with AD from cognitively healthy control subjects with high sensitivity and specificity. Cross-validation within the AIBL cohort and further validation within the ADNI cohort provides strong evidence that the identified biomarkers are important for AD diagnosis.
登录
查看更多内容
影响因子：
9.9
作者：
Lopez, O. L.;Kuller, L. H.;DeKosky, S. T.
通讯作者：
DeKosky, S. T.
影响因子：
--
作者：
Mehta, PD;Pirttilä, T;Wisniewski, HM
通讯作者：
Wisniewski, HM
影响因子：
9.9
作者：
Roe, C. M.;Fagan, A. M.;Morris, J. C.
通讯作者：
Morris, J. C.
影响因子：
4.2
作者：
Desikan RS;Cabral HJ;Settecase F;Hess CP;Dillon WP;Glastonbury CM;Weiner MW;Schmansky NJ;Salat DH;Fischl B;Alzheimer's Disease Neuroimaging Initiative
通讯作者：
Alzheimer's Disease Neuroimaging Initiative
影响因子：
--
作者：
Soares, Holly D.;Potter, William Z.;Pickering, Eve;Kuhn, Max;Immermann, Frederick W.;Shera, David M.;Ferm, Mats;Dean, Robert A.;Simon, Adam J.;Swenson, Frank;Siuciak, Judith A.;Kaplow, June;Thambisetty, Madhav;Zagouras, Panayiotis;Koroshetz, Walter J.;Wan, Hong I.;Trojanowski, John Q.;Shaw, Leslie M.
通讯作者：
Shaw, Leslie M.